Novartis' Alcon buys PowerVision

March 18, 2019

Alcon, Novartis' eye care division, has acquired PowerVision, a privately-held medical device development company focused on creating fluid-based intraocular lens implants.

The $ 285 million acquisition furthers Alcon's commitment to bring this innovative, accommodating lens to cataract patients throughout the world.

While most presbyopia-correcting intraocular lenses use a multifocal design that distributes light between different focal points, PowerVision's groundbreaking fluid-based design creates a continuously variable monofocal lens, utilizing the natural contraction of the eye's muscles. This technology allows the patient to actively focus on objects, just as the natural crystalline lens does in a youthful eye, providing patients with a natural, continuous range of vision.

Commercial availability of Texas-based PowerVision's IOL technology is pending significant additional development and clinical trials of the intraocular lens.

Read the press release.